The Vox Markets Podcast / Jonathan Tobin, Managing Director Arix Bioscience discusses Merck's $2.75 billion acquisition of VelosBio.

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.